Generic Medications and Blood Pressure Control in Diabetic Hypertensive Subjects
暂无分享,去创建一个
V. Howard | G. Howard | P. Muntner | M. Safford | D. Cummings | A. Letter | Valerie Prince | Abraham J. Letter
[1] J. Spence. Faculty Opinions recommendation of Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. , 2013 .
[2] P. Whelton,et al. Hypertension Control Among Newly Treated Patients Before and After Publication of the Main ALLHAT Results and JNC 7 Guidelines , 2012, Journal of clinical hypertension.
[3] W. Elliott. US Trends in Prevalence, Awareness, Treatment, and Control of Hypertension, 1988-2008 , 2011 .
[4] Qingxia Chen,et al. Impact of generic substitution decision support on electronic prescribing behavior , 2010, J. Am. Medical Informatics Assoc..
[5] J. Selby,et al. TRIALS STUDY PROTOCOL Open Access Study protocol: The Adherence and , 2022 .
[6] T. Brennan,et al. Changes in Drug Use and Out‐of‐Pocket Costs Associated with Medicare Part D Implementation: A Systematic Review , 2010, Journal of the American Geriatrics Society.
[7] B. Egan,et al. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. , 2010, JAMA.
[8] Kevin A Peterson,et al. Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus , 2011 .
[9] K. Chan,et al. Medication adherence and use of generic drug therapies. , 2009, The American journal of managed care.
[10] W. Elliott. Resistant Hypertension: Diagnosis, Evaluation, and Treatment: A Scientific Statement From the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research , 2009 .
[11] M Alan Brookhart,et al. Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis. , 2008, JAMA.
[12] Daniel W. Jones,et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. , 2008, Circulation.
[13] Á. Benedict,et al. The economic consequences of noncompliance in cardiovascular disease and related conditions: a literature review , 2008, International journal of clinical practice.
[14] J. Newhouse,et al. Hypertension treatment in a medicare population: adherence and systolic blood pressure control. , 2007, Clinical therapeutics.
[15] C. Lewis,et al. Understanding racial disparities in hypertension control: intensity of hypertension medication treatment in the REGARDS study. , 2007, Ethnicity & disease.
[16] Anthonius de Boer,et al. Generic Substitution of Antihypertensive Drugs: Does it Affect Adherence? , 2006, The Annals of pharmacotherapy.
[17] C. Moy,et al. The Reasons for Geographic and Racial Differences in Stroke Study: Objectives and Design , 2005, Neuroepidemiology.
[18] Aesha Drozdowski,et al. Standards of medical care in diabetes. , 2004, Diabetes care.
[19] Daniel W. Jones,et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. , 2003, JAMA.
[20] J. Mckenney,et al. National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) , 2002 .
[21] Philip D. Harvey,et al. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38 , 1998, BMJ.
[22] V. Basevi. Standards of Medical Care in Diabetes—2011 , 2011, Diabetes Care.
[23] L. Green,et al. Concurrent and Predictive Validity of a Self-reported Measure of Medication Adherence , 1986, Medical care.